SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

Molecular Cancer Therapeutics

Volumn 5, Issue 7, 2006, Pages 1774-1782

  Patyna, Shem ^a   Laird, A Douglas ^c   Mendel, Dirk B ^e   O'Farrell, Anne Marie ^b   Liang, Chris ^f   Guan, Huiping ^h   Vojkovsky, Tomas ^f   Vasile, Stefan ^g   Wang, Xueyan ⁱ   Chen, Jeffrey ^a   Grazzini, Maren ^a   Yang, Cheng Y ^j   Haznedar, Joshua O ^e   Sukbuntherng, Juthamas ^d   Zhong, Wei Zhu ^a   Cherrington, Julie M ^b   Hu Lowe, Dana ^a  

^a PFIZER INC   (United States)

^b Phenomix Corporation   (United States)

^c EXELIXIS INC   (United States)

^d CELERA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g BURNHAM INSTITUTE   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ Metabolex Inc   (United States)

^j GILEAD SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 [(5 FLUORO 2 OXO 1,2 DIHYDRO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLIN 4 YLPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE MALEATE; CYCLOPHOSPHAMIDE; DOCETAXEL; DRUG VEHICLE; FLT3 LIGAND; LIGAND; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SU 14813; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR CELL; TUMOR CELL LINE; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; INDOLES; MICE; MORPHOLINES; NEOPLASMS; PROTEIN KINASE INHIBITORS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748293111     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0333     Document Type: Article

References (43)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-25.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. MET, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
3. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 2003;12:51-64.
4. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004;91:1-30.
5. Herbst RS, Fukuoka M, Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65.
6. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-9.
7. Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov 2004;3:995-6.
8. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904-13.
9. Lokker N, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002;62:3729-35.
10. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
11. Tamborini E, Bonadiman L, Negri T, et al. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004;10:8214-9.
12. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol 2002;9:274-81.
13. Beghini A, Larizza L, Cairoli R, Morra E. c-kit activating mutations and mast cell proliferation in human leukemia. Blood 1998;92:701-2.
14. Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 2002;116:744-57.
15. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
16. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
17. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006;5:1280-9.
18. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
19. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
20. Demetri GD, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) [abstract 3001]. J Clin Oncol 2004;22:3001.
21. Maki RG, Fletcher JA, Heinrich MC, et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). American Society of Clinical Oncology Meeting, Orlando Florida; 2005. Abstract 9011.
22. Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). American Society of Clinical Oncology Meeting, Orlando Florida; 2005. Abstract 4508.
23. Miller KD, Burstein HJ, Elias AD, et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). American Society of Clinical Oncology Meeting, Orlando Florida; 2005. Abstract 563.
24. SUTENT (sunitinib malate) prescribing information. New York (NY): Pfizer. Inc.; 2006.
25. Laird AD, Christensen JG, Li G, et al. SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002;16:681-90.
26. Mendel DB, Laird AD, Smolich B, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15:29-41.
27. Christensen JG, Schreck RE, Chan E, et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 2001;7:4230-8.
28. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-60.
29. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66.
30. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-95.
31. Roberts WG, Whalen PM, Soderstrom E, et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosone kinase inhibitor, CP-673,451. Cancer Res 2005;65:957-66.
32. Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (Bethesda) 1990;82:1113-8.
33. Institute of Laboratory Animal Resources Commission on Life Sciences. Guide for the care and use of laboratory animals. Washington (District of Columbia): National Academy Press; 1996.
34. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
35. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
36. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
37. Kim JA. Targeted therapies for the treatment of cancer. Am J Surg 2003;186:264-8.
38. Sun L, Tran N, Liang C, et al. Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ tyrosine kinases. J Med Chem 2000;43:2655-63.
39. Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003;307:476-80.
40. Baselga J, Arribas J. Treating cancer's kinase "addiction." Nat Med 2004;10:786-7.
41. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32-40S.
42. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-8.
43. Fiedler W, Giaccone G, Lasch P, et al. Phase I Study of SU-014813, a novel oral multi-targeted receptor tyrosine kinase (RTK) inhibitor. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Philadelphia, Pennsylvania; 2005. Abstract B119.